Targeted therapy has revolutionized the treatment landscape of various types of cancer. Currently, HER3 based drugs are not available in the market or have not received any approval from the FDA. However, several American and European players are continuously working to seek approval for HER3 based drugs, and they are heavily investing in advanced technology and R&D activities for product innovation and development. The HER3-based drugs are expected to enter the market by 2025, which is likely to revolutionize cancer treatment across Europe and America.
PIPELINE PRODUCTS
Name |
Research code |
Research phase |
Company |
Indications |
KTN-3379 |
KTN-3379; CDX-3379, KTN3379; CDX3379 |
Phase Ⅱ |
Med Immune, Koll tan |
KTN-3379 |
AllitinibTosylate |
AST-6; ALS-1306; AST-1306 |
Phase Ⅱ |
Shanghai Allist Pharmaceuticals |
AllitinibTosylate |
AC-480 |
AC-480; BMS-599626, AC480; BMS599626, AC 480; BMS 599626 |
Phase Ⅰ |
Ambit biosciences |
AC-480 |
Patritumab |
AMG-888; U3-1287, AMG888, U31287 |
Phase Ⅲ |
Daiichi Sankyo, Amgen |
Patritumab |
SPC-3920 |
SPC-3920; EZN-3920 |
Preclinical |
Roche |
SPC-3920 |
Seribantumab |
MM-121; SAR-256212; 1N3L70MDFX (UNII code) |
Phase Ⅱ |
Merrimack, Sanofi |
Seribantumab |
Sapitinib |
AZD-8931 |
Phase Ⅱ |
AstraZeneca |
Sapitinib |
ISU-104 |
ISU-104 |
Phase Ⅰ |
ISU Abxis |
ISU-104 |
In the last few years, the global market has witnessed significant growth in the prevalence of various types of cancer across the globe. To address the dire situation, numerous players are constantly working on drug development and FDA approval. Currently, several HER3 drugs are in the pipeline and waiting for FDA approval. The study suggests that only HER3 acting drugs may not be that effective, but a combination with any chemotherapy drug can become a prominent option to treat cancers. Apart from this, many players are putting efforts into developing monoclonal antibodies against HER3.
We believe that rapidly growing drug resistance is one of the prime factors for drug failure as it limits the efficacy of many targeted therapies, including mono-/bispecific antibodies and small-molecule inhibitors. As per the clinical studies and findings, it is suggested that concomitant suppression of HER3 with other receptor tyrosine kinases (RTKs), such as EGFR family members, may appear to be helpful in attaining better clinical benefits. Moreover, the combination of HER-2 and HER-3 can offer a promising opportunity for treating colorectal cancer in the years to come.
Got questions about your regional growth of
Receptor Tyrosine Protein Kinase ERBB3 Market?
Just drop us a line or call on +1 646 480 7505
Key Highlights
Key Players
Receptor Tyrosine Protein Kinase ERBB 3 Market: Segmentation
By Product Type
By Application
By Region
" Crucial Insights The Report Provides:"
* Known and Unknown Adjacencies Influencing the Growth of Market
* Explorable Revenue Sources
* Customer Behaviour Analysis
* Target Partners
* Customized Geographical Data Based on Customers as well as Competitors
* Analysis of Market Size and CAGR between the Forecast Periods